FdaApplication
NDA 020287
Identifiers
- fda_app_no: NDA020287
Properties
| Property | Value |
|---|---|
| applicant_name | PFIZER INC |
| application_type | NDA |
| approval_date | 1994-12-22 |
Revenue by product
FRAGMIN
| Period | Revenue |
|---|---|
| Q4 2023 | $63.0M |
| Q3 2023 | $57.0M |
| Q2 2023 | $59.0M |
| Q1 2023 | $58.0M |
| Q4 2022 | $67.0M |
| Q3 2022 | $60.0M |
| Q2 2022 | $72.0M |
| Q1 2022 | $70.0M |
| Q4 2021 | $82.0M |
| Q3 2021 | $74.0M |
| Q2 2021 | $77.0M |
| Q1 2021 | $71.0M |
| Q4 2020 | $74.0M |
| Q3 2020 | $60.0M |
| Q2 2020 | $58.0M |
| Q1 2020 | $59.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (12)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| FRAGMIN | DALTEPARIN SODIUM | 2,500IU/0.2ML (12,500IU/ML) | INJECTABLE;SUBCUTANEOUS |
| FRAGMIN | DALTEPARIN SODIUM | 10,000IU/4ML (2,500IU/ML) | INJECTABLE;SUBCUTANEOUS |
| FRAGMIN | DALTEPARIN SODIUM | 7,500IU/0.3ML (25,000IU/ML) | INJECTABLE;SUBCUTANEOUS |
| FRAGMIN | DALTEPARIN SODIUM | 18,000IU/0.72ML (25,000IU/ML) | INJECTABLE;SUBCUTANEOUS |
| FRAGMIN | DALTEPARIN SODIUM | 7,500 IU/0.75ML | INJECTABLE;INJECTION |
| FRAGMIN | DALTEPARIN SODIUM | 15,000IU/0.6ML (25,000IU/ML) | INJECTABLE;SUBCUTANEOUS |
| FRAGMIN | DALTEPARIN SODIUM | 12,500IU/0.5ML (25,000IU/ML) | INJECTABLE;SUBCUTANEOUS |
| FRAGMIN | DALTEPARIN SODIUM | 5,000IU/0.2ML (25,000IU/ML) | INJECTABLE;SUBCUTANEOUS |
| FRAGMIN | DALTEPARIN SODIUM | 10,000IU/0.4ML (25,000IU/ML) | INJECTABLE;SUBCUTANEOUS |
| FRAGMIN | DALTEPARIN SODIUM | 95,000IU/3.8ML (25,000IU/ML) | INJECTABLE;SUBCUTANEOUS |
| FRAGMIN | DALTEPARIN SODIUM | 95,000IU/9.5ML (10,000IU/ML) | INJECTABLE;SUBCUTANEOUS |
| FRAGMIN | DALTEPARIN SODIUM | 10,000IU/ML (10,000IU/ML) | INJECTABLE;SUBCUTANEOUS |
12 products